KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Assets (2016 - 2025)

Historic Current Assets for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $2.7 billion.

  • Sarepta Therapeutics' Current Assets rose 137.56% to $2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 billion, marking a year-over-year increase of 137.56%. This contributed to the annual value of $3.1 billion for FY2024, which is 1915.74% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Current Assets stood at $2.7 billion for Q3 2025, which was up 137.56% from $2.7 billion recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Current Assets ranged from a high of $3.1 billion in Q4 2024 and a low of $2.2 billion during Q3 2021
  • For the 5-year period, Sarepta Therapeutics' Current Assets averaged around $2.5 billion, with its median value being $2.5 billion (2022).
  • As far as peak fluctuations go, Sarepta Therapeutics' Current Assets tumbled by 1083.47% in 2021, and later soared by 2016.28% in 2022.
  • Sarepta Therapeutics' Current Assets (Quarter) stood at $2.6 billion in 2021, then dropped by 1.78% to $2.6 billion in 2022, then increased by 0.84% to $2.6 billion in 2023, then grew by 19.16% to $3.1 billion in 2024, then decreased by 11.43% to $2.7 billion in 2025.
  • Its last three reported values are $2.7 billion in Q3 2025, $2.7 billion for Q2 2025, and $2.4 billion during Q1 2025.